Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
about
Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyLysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.Inhibition of Staphylococcus aureus by lysostaphin-expressing Lactobacillus plantarum WCFS1 in a modified genital tract secretion mediumDepletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris.Peptidoglycan hydrolases-potential weapons against Staphylococcus aureusMechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.Susceptibility of methicillin-resistant Staphylococcus aureus to lysostaphin.Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonizationLysostaphin in treatment of neonatal Staphylococcus aureus infection.Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit.Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing.
P2860
Q28235095-DD09D657-065C-4A32-AE22-38732B582F4AQ28379547-8AF8A667-4F00-434F-B977-8170DCE7CD40Q30574330-57D52F09-547A-4C75-B670-ACDE1B54D6DEQ33977229-7E7CAC53-5E0A-4E1E-B2D6-DC73AE2C2619Q35599270-3450FFB9-861D-4E72-B4BE-09F9BC7ED21AQ35638576-B0552E56-FB96-49FD-93D2-CCF235B5A917Q37713110-7558CF51-6002-4E5D-92CB-29EA3D69F191Q38053102-17F2316A-30B7-420C-9D67-616BFB024C41Q39477127-10BDC151-E7AD-4231-9099-5B30F37C0A5CQ39651918-9DAC5AEA-63C4-4830-9A03-11B6B3E3ACE8Q40199495-283BFC0D-88B7-471D-A51E-856944DACB74Q40634630-803FB60E-B38B-40F4-A61E-B9B37B197C6DQ40968033-93CEAA98-39CD-4928-A76A-93A0AE2D3567Q42080630-2DBFABBE-94F4-4BA9-B2B9-BE3AC5C923EDQ43755005-C683300A-11BC-490D-B19C-C84DB7D83674Q46034505-466A0B16-020C-47F6-8046-8A7E6343C948Q46173172-D60A9B4E-25EC-4DAE-A1F3-DE53EEA1D74BQ54212204-46B433C8-D90F-4605-A8F2-C4A6C1A93F1A
P2860
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年学术文章
@wuu
1974年学术文章
@zh-cn
1974年学术文章
@zh-hans
1974年学术文章
@zh-my
1974年学术文章
@zh-sg
1974年學術文章
@yue
1974年學術文章
@zh
1974年學術文章
@zh-hant
name
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@en
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@nl
type
label
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@en
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@nl
prefLabel
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@en
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@nl
P2093
P1476
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.
@en
P2093
Artenstein MS
Flannery EP
Thornsvard C
P304
P356
10.1056/NEJM197408012910507
P407
P577
1974-08-01T00:00:00Z